Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria

Phenylketonuria (PKU) is a rare metabolic disorder that requires life-long management to reduce phenylalanine (Phe) concentrations within the recommended range. The availability of pegvaliase (PALYNZIQ？, an enzyme that can metabolize Phe) as a new therapy necessitates the provision of guidance for its use